Biotech m a news today?

Biotech Merger and Acquisition News Today

What biotechnology companies are making news today?

Today's biotechnology news includes updates on several companies and their activities. Veru Inc. [1] announced that its Phase 3 COVID-19 treatment drug, sabizabulin, has been granted a pediatric investigational new drug application by the U.S. Food and Drug Administration (FDA) [1]. This development allows for the initiation of a pediatric study for the drug [1].

Separately, the U.S. Securities and Exchange Commission (SEC) has initiated a review of Atossa Therapeutics Inc.'s [2] Form 10-K filing for the fiscal year ended December 31, 2023 [2]. The SEC's Division of Corporation Finance has requested additional information regarding certain disclosures within the filing [2]. Atossa Therapeutics stated it is reviewing the SEC's comments and will respond accordingly [2].

What does this mean for sabizabulin?

The FDA's acceptance of the pediatric investigational new drug application is a step towards potentially expanding the use of sabizabulin to younger populations [1]. This follows previous evaluations of the drug for COVID-19 treatment in adults [1].

Why is the SEC reviewing Atossa Therapeutics' filing?

The SEC's review of Atossa Therapeutics' Form 10-K is a standard regulatory process to ensure accurate and complete disclosure of financial and operational information by public companies [2]. The specific details of the SEC's request have not been disclosed [2].

What are the latest developments in the broader biotech sector?

Mergers and acquisitions continue to be a significant theme in the biotechnology industry. Companies are actively seeking to acquire or merge with others to expand their pipelines, gain access to new technologies, or consolidate market share. Investors and analysts closely monitor these activities for potential market shifts and opportunities.

Sources:

1. Veru Inc. https://www.veruinc.com/
2. Atossa Therapeutics Inc. https://www.atossatherapeutics.com/